Industry hits jackpot in Brazil – quicker clinical trial approvals
This article was originally published in Scrip
Interfarma, which represents the R&D-based pharmaceutical industry in Brazil, has thanked the national medicines regulator, ANVISA, for its recent proposals to improve the clinical trial application procedure. If enacted, the measures could attract more clinical trials to the country and shave up to 90 days off the approval process for 80% of trials, says the organisation.
You may also be interested in...
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer's COVID-19 vaccine in 2021 and beyond.
How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.